Clicky

  • Login
  • Register
  • Submit Your Content
  • Contact Us
Thursday, December 5, 2024
World Tribune
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
Submit
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
No Result
View All Result
World Tribune
No Result
View All Result

Zepbound (tirzepatide) superior to Wegovy (semaglutide), says Lilly-funded clinical trial

December 5, 2024
in Business
Reading Time: 3 mins read
A A
Zepbound (tirzepatide) superior to Wegovy (semaglutide), says Lilly-funded clinical trial
0
SHARES
ShareShareShareShareShare

Zepbound (tirzepatide) superior to Wegovy (semaglutide), says Lilly-funded clinical trial

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a recent randomized clinical trial backed by Lilly.

READ ALSO

Gensler reveals 2025’s hottest design trends: mixed-use districts, affordable housing, better offices

UBS stunned by mafia analogy at whistleblower pressure trial

After injecting the medications weekly for nearly 17 months, patients who took Zepbound lost 20.2% of their body weight (50.3 pounds) on average, while Wegovy patients lost 13.7% (33.1 pounds), Lilly announced in a Dec. 4 news release. In addition, Zepbound yielded a 47% greater relative weight loss over its rival, and 31.6% of Zepbound patients lost at least 25% of their body weight, compared to 16.1% of Wegovy users.

“Given the increased interest around obesity medications, we conducted this study to help health care providers and patients make informed decisions about treatment choice,” Dr. Leonard Glass, senior vice president of global medical affairs at Lilly Cardiometabolic Health, said in the news release. “Zepbound is in a class of its own as the only FDA-approved dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication, and it’s changing how millions of people manage this chronic disease.”

The trial involved 751 U.S. adults 18 and older who had either obesity, or overweight with at least one of the following medical conditions: heart disease, high blood pressure, high cholesterol, or obstructive sleep apnea. They received the maximum tolerated dose of Zepbound (10 mg or 15 mg) or Wegovy (1.7 mg or 2.4 mg) for 72 weeks. (No participant had diabetes; Lilly markets tirzepatide as Mounjaro to people with Type 2 diabetes, while Novo Nordisk does the same for semaglutide as Ozempic.)

The results have not yet been peer-reviewed, however, Lilly indicated they would in 2025 be published in a peer-reviewed journal and presented at an unspecified medical meeting.

Lilly funded the clinical trial, the goal of which, the company said, “was to demonstrate Zepbound’s superiority in percent change from baseline in body weight at 72 weeks compared to Wegovy.” This shouldn’t necessarily raise eyebrows, says Dr. W. Scott Butsch, director of obesity medicine at Cleveland Clinic’s Bariatric and Metabolic Institute.

“We should always look at the funding source as a potential bias of the study,” Butsch tells Fortune via email. “But this study was well-designed and we should believe the data.”

What’s more, the trial results are similar to those of a study—not financed by Lilly—published earlier this year in the journal JAMA Internal Medicine, Dr. Holly Lofton, an obesity medicine specialist at NYU Langone Health, points out to Fortune. That research showed that 42.3% of people taking tirzepatide, the generic name for Zepbound, lost at least 15% of their body weight within a year, compared to 15% of people taking semaglutide, the generic name for Wegovy.

Should I take Zepbound instead of Wegovy?

Both Zepbound and Wegovy are prescription medications, so you must consult your health care provider if you have concerns about taking one over the other. They’re also not the only weight loss medications out there, and your doctor can help you determine which may be appropriate for you, given your weight-loss goals and medical history.

And while the results of Lilly’s trial are promising, they shouldn’t be your only consideration in requesting a weight-loss medication, Lofton says.

“Both drugs demonstrate meaningful weight loss of over 10%, which can improve or ameliorate many weight related medical conditions,” Lofton tells Fortune via email. “Prescribers and patients should always consider safety, efficacy, and accessibility of the medication when deciding which drug is best for the patient.”

Butsch echoes, “From the patient’s perspective, I don’t think that these study results will change the public demand for tirzepatide, nor result in switching medications. It reinforces that there are currently two highly effective medications, but so many factors—cost, coverage, et cetera—that are barriers to access.”

For more on weight management:

Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up for free today.

Credit: Source link

ShareTweetSendSharePin
Previous Post

SMU, Iowa State ADs get heated over latest CFP rankings

Next Post

Sundar Pichai says he’d love to compare Google, Microsoft’s AI models

Related Posts

Gensler reveals 2025’s hottest design trends: mixed-use districts, affordable housing, better offices
Business

Gensler reveals 2025’s hottest design trends: mixed-use districts, affordable housing, better offices

December 5, 2024
UBS stunned by mafia analogy at whistleblower pressure trial
Business

UBS stunned by mafia analogy at whistleblower pressure trial

December 4, 2024
The latest must-have luxury real estate amenity? Surf pools
Business

The latest must-have luxury real estate amenity? Surf pools

December 4, 2024
Celsius Network founder pleads guilty to fraud charges over collapse of crypto lending platform
Business

Celsius Network founder pleads guilty to fraud charges over collapse of crypto lending platform

December 4, 2024
Jobs that pay 0,000+ require advanced degrees and in-person working, research shows
Business

Jobs that pay $200,000+ require advanced degrees and in-person working, research shows

December 4, 2024
The 4 ‘fatal flaws’ in Tesla’s bid to award Elon Musk 0 billion, according to the judge who dashed his pay
Business

The 4 ‘fatal flaws’ in Tesla’s bid to award Elon Musk $100 billion, according to the judge who dashed his pay

December 4, 2024
Next Post
Sundar Pichai says he’d love to compare Google, Microsoft’s AI models

Sundar Pichai says he’d love to compare Google, Microsoft’s AI models

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

What's New Here!

Elon Musk’s net worth rockets to over 0 billion as Trump win fuels optimism for Tesla and SpaceX

Elon Musk’s net worth rockets to over $300 billion as Trump win fuels optimism for Tesla and SpaceX

November 9, 2024
Trump Media DJT shares gain as presidential election voting nears end

Trump Media DJT shares gain as presidential election voting nears end

November 6, 2024
U.S. can adopt crypto regulation ‘quickly’ now

U.S. can adopt crypto regulation ‘quickly’ now

December 2, 2024
Who could Trump name to replace SEC Chair Gary Gensler?

Who could Trump name to replace SEC Chair Gary Gensler?

November 10, 2024
Beating the U.S. but keeping control of tech

Beating the U.S. but keeping control of tech

December 3, 2024
4 tips for handling the holidays as a newly single person

4 tips for handling the holidays as a newly single person

November 30, 2024
Google stock plunges 5% after DOJ calls for Chrome sale

Google stock plunges 5% after DOJ calls for Chrome sale

November 22, 2024

About

World Tribune is an online news portal that shares the latest news on world, business, health, tech, sports, and related topics.

Follow us

Recent Posts

  • Gensler reveals 2025’s hottest design trends: mixed-use districts, affordable housing, better offices
  • Mike Florio proposes blockbuster Kyle Shanahan trade to Bears
  • Sundar Pichai says he’d love to compare Google, Microsoft’s AI models
  • Zepbound (tirzepatide) superior to Wegovy (semaglutide), says Lilly-funded clinical trial

Newslatter

Loading
  • Submit Your Content
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2024 World Tribune - All Rights Reserved!

No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food

© 2024 World Tribune - All Rights Reserved!

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In